Apyx Medical Corp: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 3, 2017 and accepted by EDGAR at Nov 3, 2017, 07:42 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-07-01 to 2017-09-30 | $4.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2017-01-01 to 2017-09-30 | $13.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2017-07-01 to 2017-09-30 | $4.6m | us-gaap:GrossProfit |
| Gross profit | 9 months2017-01-01 to 2017-09-30 | $13.9m | us-gaap:GrossProfit |
| Research and development | 3 months2017-07-01 to 2017-09-30 | $610.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-07-01 to 2017-09-30 | $2.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2017-01-01 to 2017-09-30 | $8.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$4.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $6.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $15.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$1.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$4.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 31,078,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 30,932,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | −$4.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $431.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $9.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $22.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $30.7m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $4.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $8.2m | us-gaap:Liabilities |
| Long-term debt | At period end2017-09-30 | $2.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-09-30 | $239.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-09-30 | $22.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-17-000064. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.